Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

NewLink Genetics NLNK

Healthcare Biotechnology
Lumos Pharma Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare and neglected diseases. The company's therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, is in late-stage clinical development for the treatment of Pediatric Growth Hormone Deficiency (PGHD).


NDAQ:NLNK - Post by User

NewLink Genetics > WHO will test Newlink
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Comment by jawcrusheron Oct 17, 2014 6:27pm
387 Views
Post# 23039526

RE:WHO will test Newlink

RE:WHO will test NewlinkWHO will receive vaccine Monday

https://www.cbc.ca/news/politics/ebola-vaccine-to-be-sent-to-who-on-monday-for-clinical-trials-1.2803731
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities